Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus

Coronavirus disease (COVID-19) appeared in December 2019 in the Chinese city of Wuhan and has quickly become a global pandemic. The disease is caused by the severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2), an RNA beta coronavirus phylogenetically similar to SARS coronavirus. To dat...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neurology 2021-11, Vol.268 (11), p.3961-3968
Main Authors: Centonze, Diego, Rocca, Maria A., Gasperini, Claudio, Kappos, Ludwig, Hartung, Hans-Peter, Magyari, Melinda, Oreja-Guevara, Celia, Trojano, Maria, Wiendl, Heinz, Filippi, Massimo
Format: Article
Language:English
Subjects:
Consensus
Coronaviruses
COVID-19
COVID-19 Vaccines
Humans
Immunization
Immunomodulation
Immunosuppressive agents
Medicine
Medicine & Public Health
Multiple sclerosis
Multiple Sclerosis - drug therapy
Neurology
Neuroradiology
Neurosciences
Original Communication
Pandemics
Phylogeny
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Vaccination
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Coronavirus disease (COVID-19) appeared in December 2019 in the Chinese city of Wuhan and has quickly become a global pandemic. The disease is caused by the severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2), an RNA beta coronavirus phylogenetically similar to SARS coronavirus. To date, more than 132 million cases of COVID19 have been recorded in the world, of which over 2.8 million were fatal ( https://coronavirus.jhu.edu/map.html ). A huge vaccination campaign has started around the world since the end of 2020. The availability of vaccines has raised some concerns among neurologists regarding the safety and efficacy of vaccination in patients with multiple sclerosis (MS) taking immunomodulatory or immunosuppressive therapies.
ISSN:0340-5354
1432-1459
DOI:10.1007/s00415-021-10545-2